Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex (GNPX), a clinical-stage gene therapy company, announced its support for the FDA's initiative aimed at expediting gene therapy development for rare diseases. The FDA's new approach will allow biomarkers to substitute for traditional biological indicators in clinical trials, potentially accelerating approval processes. Rodney Varner, CEO, emphasized that this initiative is beneficial for advancing Genprex's pipeline of gene therapies, particularly for patients with limited treatment options in cancer and diabetes. The company is utilizing its proprietary ONCOPREX Nanoparticle Delivery System for its oncology program, currently in clinical trials.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announces that Dr. Hemant Kumar, Chief Manufacturing and Technology Officer, will speak at the Bioprocessing Summit Europe in Barcelona, Spain from March 14-16, 2023. His presentation titled Managing Headwinds Due to CDMO's M&A Activities will discuss how recent mergers and acquisitions in the Contract Development and Manufacturing Organization (CDMO) sector affect gene therapy innovations. Dr. Kumar emphasizes the need for partnerships to navigate increased costs and regulatory delays, highlighting Genprex's commitment to developing life-changing therapies for cancer and diabetes. More details can be found at www.genprex.com.
Genprex, a clinical-stage gene therapy company focusing on treatments for cancer and diabetes, has announced its participation in two major conferences in March 2023. The Roth Conference will occur from March 12-14 in Laguna Niguel, California, and the BIO-Europe Spring will take place from March 20-22 in Basel, Switzerland. CFO Ryan Confer will represent Genprex at the Roth Conference, while multiple executives will attend BIO-Europe Spring. CEO Rodney Varner expressed enthusiasm about showcasing their innovative gene therapies, including updates on the REQORSA clinical trial for lung cancer and data on therapies for Type 1 diabetes.
Genprex, Inc. (NASDAQ: GNPX) announced a registered direct offering with a healthcare-focused institutional investor, involving 3,809,524 shares and warrants priced at $1.05 per share. The warrants will have an exercise price of $1.10 and expire in five years. The offering, expected to close on or about March 1, 2023, will generate approximately $4 million in gross proceeds, earmarked for general working capital. A.G.P./Alliance Global Partners acts as the sole placement agent. This transaction is conducted under an existing shelf registration statement filed with the SEC.
Genprex, Inc. (NASDAQ: GNPX) has showcased promising results from a non-human primate study on a new gene therapy for Type 1 diabetes at the ATTD 2023 conference. The study revealed statistically significant decreases in insulin requirements, increases in c-peptide levels, and improved glucose tolerance. The gene therapy, developed in collaboration with the University of Pittsburgh, utilizes an adeno-associated virus to deliver Pdx1 and MafA genes directly to the pancreas. These results, indicating the formation of insulin-producing cells, pave the way for potential human clinical trials.
Genprex, Inc. has entered into an exclusive licensing agreement with the University of Pittsburgh, allowing access to innovative gene therapy technologies for treating Type 1 and Type 2 diabetes. This agreement grants Genprex exclusive rights to a patent application for GPX-003, aimed at rejuvenating beta cells, while GPX-002 targets Type 1 diabetes by transforming alpha cells into insulin-producing cells. This marks the third technology license for Genprex this year, enhancing its intellectual property portfolio and diabetes therapy initiatives.
Genprex (GNPX) announced that researchers from the University of Pittsburgh will present preclinical data on its gene therapy for Type 1 diabetes at the ATTD 2023 conference from February 22-25 in Berlin, Germany. The gene therapy aims to transform pancreatic alpha cells into beta-like cells producing insulin, potentially offering long-term solutions for diabetes patients. The presentation is expected to highlight the innovative infusion process using an adeno-associated virus vector. This research supports the therapeutic potential of Genprex's novel approach in changing diabetes treatment.
Genprex, Inc. (NASDAQ: GNPX) announced an exclusive license agreement with the University of Pittsburgh, enhancing its gene therapy capabilities for Type 1 diabetes. This agreement grants worldwide access to technology that modulates autoimmunity by transforming macrophages. The technology complements Genprex's existing diabetes therapies, potentially improving outcomes for over 37 million U.S. diabetes patients. Previous successes include significant blood glucose restoration in diabetic mouse models, with promising results expected in non-human primates. CEO Rodney Varner emphasized the strategic importance of expanding their intellectual property portfolio.
Genprex, Inc. (GNPX) announced the approval from its Safety Review Committee (SRC) to advance to the third and final cohort in the Phase 1 dose escalation of the Acclaim-1 clinical trial for REQORSA® in combination with Tagrisso® to treat late-stage non-small cell lung cancer (NSCLC). This decision confirms the drug's favorable safety profile, following prior FDA Fast Track Designation in 2020. The trial aims to evaluate toxicity and efficacy, with expectations to complete patient enrollment in early 2023.
Genprex, Inc. (NASDAQ: GNPX) will present its gene therapies for cancer and diabetes at the RHK 2022 Disruptive Growth Conference on December 6, 2022, at 2:40 p.m. ET in New York City. Catherine Vaczy, Executive Vice President and Chief Strategy Officer, will share insights on the company's innovative therapies, including the ONCOPREX® delivery system for cancer treatment and a new gene therapy approach for diabetes. Investors can engage in Q&A and one-on-one meetings after the presentation.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
